Archives
-
Metoprolol Research: From Receptor Blockade to Assay Design
2026-09-17
Metoprolol is a selective beta1-adrenoceptor antagonist with applications spanning cardiovascular disease research and mechanistic studies of inflammation, cancer, and angiogenesis. This article explains how integrated pharmacokinetic evidence can improve assay architecture, controls, and interpretation without confusing findings from MASH models with Metoprolol-specific evidence.
-
High-Content Stem Cell Screening in Schistosoma
2026-09-17
Perera, Chioni, and Walker developed a quantitative high-content assay that measures somatic neoblast proliferation in developmentally advanced liver-stage Schistosoma mansoni schistosomula. Screening a 280-compound stem cell-focused collection identified prioritized molecules that disrupted parasite development and stem cell proliferation, offering a more informative route to anti-schistosomal lead discovery than morphology or motility alone.
-
ML-7 Hydrochloride: From MLC Signal to Assay
2026-09-16
ML-7 hydrochloride is a myosin light chain kinase inhibitor for dissecting MLC phosphorylation, contractility, barrier function, and cell invasion. This article presents an assay-first framework that connects cardiovascular models with mechanistic insights from breast cancer research.
-
NF 340: Mapping P2Y11 Signaling in Invasion
2026-09-16
Explore how the P2Y11 antagonist NF 340 helps dissect the connection between QPRT, purinergic signaling, and myosin light-chain phosphorylation. This guide translates the reference study into practical assay decisions while clarifying compound handling, controls, and interpretation limits.
-
15-PGDH Inhibition Preserves Muscle During Weight Loss
2026-09-15
The reference study shows that inhibiting 15-PGDH can improve muscle regeneration and strength recovery during semaglutide-associated weight loss in obese mice. Its central advance is the combination of a GLP-1 receptor agonist with a regenerative intervention that improves postinjury muscle quality without reducing weight-loss efficacy.
-
Crizotinib in Patient-Derived Cancer Assembloids
2026-09-15
Patient-derived gastric cancer assembloids expose how stromal context can reshape drug response. This thought-leadership guide shows how Crizotinib hydrochloride can be positioned as a mechanistic probe for ALK, c-Met, and ROS1 signaling in more physiologically relevant cancer biology research.
-
Z-VAD-FMK Workflow for Apoptosis and Ferroptosis
2026-09-14
Z-VAD-FMK turns a cell-death assay into a causal test: block caspase-dependent apoptosis while independently tracking the TFEB–NRF2 ferroptosis axis described in NSCLC. This workflow combines practical dosing and stock-handling guidance with controls that distinguish pathway rescue from nonspecific cytoprotection.
-
Cell Cycle Assay Kit for Cancer Cell-Cycle Analysis
2026-09-14
Use DNA-content profiling to distinguish G0/G1, S, and G2/M populations while flagging apoptotic sub-G1 events in treatment-response studies. This practical workflow shows how to apply PI/RNase A staining to colorectal cancer experiments inspired by recent CGF research, with controls and troubleshooting built in.
-
Verapamil HCl Workflows for Calcium Signaling
2026-09-13
Verapamil HCl provides a practical perturbation tool for L-type calcium channel studies, with applications spanning calcium channel inhibition in myeloma cells, transporter biology, and inflammatory disease models. This guide translates the evidence into staged assay workflows, controls, and troubleshooting decisions for more reproducible results.
-
Carfilzomib (PR-171): A Proteostasis Assay Guide
2026-09-12
Carfilzomib (PR-171) is an irreversible proteasome inhibitor whose value extends beyond simple viability testing. This guide develops a mechanism-to-readout framework linking proteasome-mediated proteolysis inhibition with ER-stress biomarkers, apoptosis interpretation, and combination-assay design.
-
METTL16–SENP3–LTF Drives HCC Ferroptosis Resistance
2026-09-11
Wang et al. identify a METTL16–SENP3–LTF axis that lowers the labile iron pool and protects hepatocellular carcinoma cells from ferroptosis. By integrating m6A-focused molecular assays with organoids, xenografts, genetically modified mice, and human samples, the study connects RNA regulation, protein stability, iron handling, and tumor progression.
-
LL-37, KE-18, and KR-12 in Biofilm Control
2026-09-11
The reference study showed that the human host defense peptide LL-37 and its truncated mimetics KE-18 and KR-12 can separate antimicrobial killing from antibiofilm activity across Candida albicans, Staphylococcus aureus, and Escherichia coli. Its key practical contribution is methodological: MIC measurements and crystal violet biofilm assays should be interpreted as complementary rather than interchangeable readouts.
-
Prestained Protein Marker: Triple Color 10–250 kDa
2026-09-10
F4005 is a ready-to-use Triple color protein ladder for tracking SDS-PAGE separation, checking transfer, and estimating apparent protein size across 10–250 kDa. It is appropriate for denaturing gel and Western blot workflows, including EDTA-sensitive Phosbind systems, but it should not be treated as an exact protein-identification standard or as quantitative evidence of transfer efficiency.
-
Ionomycin Free Acid: Calcium Ionophore Guide
2026-09-10
Ionomycin free acid is a calcium ionophore research reagent that increases membrane-mediated calcium ion transport and intracellular calcium. The product is supplied in ethanol, has a reported purity of at least 95%, and supports controlled studies of calcium signaling, oocyte activation, and hypothesis-driven cancer biology.
-
S63845 MCL1 Inhibitor Workflow Guide
2026-09-09
Build a cleaner apoptosis workflow with S63845 by linking MCL1 inhibition to BAX/BAK activation, mitochondrial permeabilization, and orthogonal cell-death readouts. The guide also shows how to distinguish genuine apoptotic enhancement from ferroptosis-related assay confounding in hematological cancer research.